Pharmaceuticals & Therapeutics

After a strong 2025, Viatris unveils a plan for $650M in savings, a 10% workforce cut, and a focus on six new drugs to fuel future innovation.

Perrigo takes a massive $1.3B impairment charge and plans a 7% workforce reduction as it pivots to a 'CORE' business amid a challenging outlook.

The environmental services giant surpassed 2025 targets, driven by its GreenUp strategy, major acquisitions in water tech, and a renewed global push.

MiMedx reports record 2025 sales and a $100M buyback, but faces a major challenge from new Medicare reimbursement rules set to disrupt the wound care market.

With stellar clinical data and a full war chest, Terns is hitting the road to convince investors its leukemia drug, TERN-701, is a true disruptor.

With cash to last until 2027 but mounting losses, Alector stakes its future on its ABC platform and a pivotal Alzheimer's trial milestone.

Struggling biotech Jupiter Neurosciences presents its Parkinson's drug to elite investors at Mar-a-Lago, betting its hybrid business model can win funding.

Rgenta Therapeutics unveils a promising oral drug that targets the genetic root of Huntington's, offering a new beacon of hope for patients.

Investors sue Corcept Therapeutics, claiming the company hid FDA warnings about its key drug, relacorilant, before a 50% stock price collapse.

P4ML joins the Orphan Therapeutics Accelerator to bring shelved cures to patients, leveraging a new non-profit model and expanding access to the MENA region.

Flush with cash and nearing major clinical milestones for its neuromuscular disease pipeline, Dyne Therapeutics is set to make its case to investors.

With sales rising and key FDA milestones met, Australian biotech Immuron resets its strategy, seeking partners to fund its promising infectious disease pipeline.

With a new CEO at the helm and a pivotal trial for its lead drug on the horizon, all eyes are on PureTech's upcoming investor conference presentation.

The diabetes tech firm secures major funding for innovation and acquisitions, using a savvy financial strategy to protect current shareholder value.

New FDA-cleared Persona PLUS technology promises to increase plasma yields per donor, tackling the growing global demand for life-saving therapies.

The biotech firm secures major funding to push its promising head and neck cancer drug, ficerafusp alfa, toward regulatory approval and commercial launch.

Fueled by policy incentives and strong demand, First Solar reports robust 2025 growth and accelerates its US factory expansion, cementing its market leadership.

A new Ontario program is giving breast cancer patients access to a life-changing drug a year sooner, setting a potential new standard for Canada.

The tech firm announced progress on a major health contract, but with its stock near all-time lows, can this deal deliver a much-needed turnaround?

Kenai Therapeutics hires a Novartis M&A veteran as CBO, signaling an aggressive strategy to advance its groundbreaking iPSC cell therapy for Parkinson's disease.